title: Bevacizumab-induced hypovascular hepatocellular carcinoma treated by transarterial chemoembolization in a patient with metastatic colon cancer.
authors.forename: Jin
authors.initials: J
authors.lastname: Iwazawa
authors.forename: Shoichi
authors.initials: S
authors.lastname: Ohue
authors.forename: Naoko
authors.initials: N
authors.lastname: Hashimoto
authors.forename: Keigo
authors.initials: K
authors.lastname: Yasumasa
authors.forename: Hisashi
authors.initials: H
authors.lastname: Abe
authors.forename: Takashi
authors.initials: T
authors.lastname: Mitani
mesh_terms: D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects; D000068258:Bevacizumab; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced* / Q000000981:diagnostic imaging; D003110:Colonic Neoplasms; D006801:Humans; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D009389:Neovascularization, Pathologic / Q000139:chemically induced* / Q000000981:diagnostic imaging; D011859:Radiography
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab